Global Focus – Economic Outlook Q2-2021

Total Page:16

File Type:pdf, Size:1020Kb

Global Focus – Economic Outlook Q2-2021 Global Research Global Focus – Economic Outlook Q2-2021 Global growth – An uneven race research.sc.com Standard Chartered Global Research is available across all iOS and Android devices. Our intuitive, accessible and customisable apps* allow you to receive our reports, forecasts, audio-visual presentations and interactive data visualisation tools on-the-go. * Click the icons to download or search ‘Standard Chartered Global Research’ in the app store. If you are in scope for MiFID II and want to opt out of our Research services, please contact us. Issuer of Report Standard Chartered Bank Important disclosures and analyst certifications can be found in the Disclosures Appendix All rights reserved. Standard Chartered Bank 2021 https://research.sc.com Global Focus – Economic Outlook Q2-2021 Table of contents Global overview 3 Cameroon – Moving towards recovery 75 Global growth – An uneven race 4 Côte d’Ivoire – A series of unfortunate events 76 Where we differ from consensus 10 Ethiopia – A particularly difficult quarter ahead 77 Global charts 12 Gabon – The oil price reprieve 78 Ghana – The long reach of the COVID crisis 79 Geopolitical economics 14 Kenya – Third-wave woes 80 Biden’s democracy club 15 Mozambique – Delayed but not denied 81 Economies – Asia 20 Nigeria – Higher oil, faltering reform 82 Asia – Top charts 21 Senegal – Flaring tensions 83 Asia – Macro trackers 22 South Africa – Bracing for a third wave 84 Australia – Chugging along 24 Tanzania – Transition 86 Bangladesh – Turning around 26 Uganda – Oil to drive growth acceleration 87 China – Embarking on the 14th FYP 28 Zambia – Debt restructuring, IMF & elections 88 Hong Kong – Recovery cannot be rushed 30 Zimbabwe – Ifs, ands, and buts 90 India – FY22: A tale of two halves 32 Economies – Europe 91 Indonesia – Reviving the economy 34 Europe – Top charts 92 Japan – Challenges and opportunities ahead 36 Euro area – Cracks in the exit strategy 93 Malaysia – All-round support 38 Switzerland – Back on track in 2021 95 Nepal – Gradual pick-up 40 UK – Ahead of the curve 97 New Zealand – Hold your horses 41 Czech Republic – Infection rates soar 99 Philippines – Battling headwinds 43 Hungary – A delayed recovery 101 Singapore – Watch for the nuances 45 Poland – Resilience amid new COVID wave 103 South Korea – Tailwinds are blowing 47 Russia – Modest recovery expected 105 Sri Lanka – PBoC swap to buffer FX reserves 49 Taiwan – An upbeat start to 2021 51 Economies – Americas 107 Thailand – Confidence remains low 53 US and Canada – Top charts 108 Vietnam – Strong fundamentals 55 Latin America – Top charts 109 US – Post-pandemic bonanza 110 Economies – Middle East, North Africa and Canada – Resilient 112 Pakistan 57 Brazil – One step forward, two steps back 114 Bahrain – Balancing non-oil growth and reform 58 Chile – Taking a shine 116 Egypt – Steady as she goes 59 Colombia – Mixed blessings 118 Iraq – Devaluation amid rigid reform outlook 60 Mexico – More good than bad 119 Kuwait – Higher oil prices to ease liquidity 61 Peru – Speaking in binary 121 Lebanon – The more things change… 62 Oman – Goldilocks scenario 63 Strategy outlook 123 Pakistan – Balancing act 64 Exodus 124 Qatar – Onwards and upwards 65 Forecasts tables 130 Saudi Arabia – Shifting sands 66 Forecasts – Economies 131 Turkey – Treading carefully 67 Forecasts – FX 132 UAE – Recovery underway 68 Forecasts – GDP 133 Economies – Africa 69 Forecasts – Rates 134 Africa – Vaccine delays weigh on the outlook 70 Forecasts – Commodities 135 Africa – Top charts 72 Forecasts – Selected interbank rates by tenor 136 Angola – Oil provides a welcome respite 73 Authors 137 Botswana – Putting fiscal stabilisation first 74 Standard Chartered Global Research | 31 March 2021 2 Global overview Global Focus – Economic Outlook Q2-2021 Global growth – An uneven race A multi-speed economic recovery, with risks Razia Khan +44 20 7885 6914 [email protected] Global The scale of US fiscal stimulus and the speed of vaccine rollout have overview Head of Research, Africa and Middle East Standard Chartered Bank significantly lifted global economic prospects. We raise our 2021 global growth Edward Lee +65 6596 8252 forecast to 5.7% from 4.8%. Growth optimism has driven markets since we made our [email protected] Chief Economist, ASEAN and South Asia initial forecast in December, contributing to commodity gains and new inflation Standard Chartered Bank (Singapore) Limited concerns. However, we maintain a cautious outlook given the uneven nature of the economic recovery. economics Geopolitical The speed of vaccine rollout is a key differentiator of near-term growth prospects (Figure 1). US growth now looks likely to be front-loaded (see US – Post-pandemic bonanza). Around 30% of the US population had received at least one COVID-19 vaccine dose by end-March, enabling a faster and likely more sustained economic recovery. In Asia Europe, vaccine supply bottlenecks and the slower pace of progress have prompted us to lower our 2021 GDP forecast (see Euro area – Cracks in the exit strategy). Downside risks to growth persist given new waves of COVID and the likelihood that containment measures will need to be extended. Europe’s fiscal response to the pandemic has been more constrained relative to the US; slow progress on submitting reform plans is likely to MENAP delay disbursements from the EU’s Recovery Fund. Global growth to bounce back this China is likely to maintain robust growth this year, with the authorities tapering year following the COVID crisis; stimulus only moderately in order to safeguard the economic recovery (see China – policy is playing a key role Embarking on the 14th FYP). The People’s Bank of China (PBoC) has pledged to Africa stabilise the macro leverage ratio by making credit growth more consistent with nominal GDP growth. Rebalancing will become more important, as growth to date has been insufficiently broad-based and concentrated in exports (where demand is largely COVID-related, for example PPE or electronics) or sectors benefiting from easy credit. Consumer-related sectors such as catering, accommodation, tourism and air travel remain well below pre-pandemic levels. Europe The acceleration of industrial production growth has highlighted supply bottlenecks and the risk of rising producer inflation (Figure 3). China’s latest Five-Year Plan aims to prioritise high-quality growth by deepening supply-side reforms, expanding domestic demand and fostering home-grown innovation. Americas Figure 1: Vaccine rollout – EM clearly lags DM Figure 2: The world is experiencing another wave of % of people who have received at least one vaccine dose COVID-19 infections (daily new cases, 7DMA (’000s) 20 100 800 outlook Brazil Strategy Africa Asia India 18 90 700 European Union North America France 16 80 Poland Oceania South America Turkey 600 14 70 Germany 12 World 60 World (RHS) 500 US (RHS) 10 50 400 Forecasts 8 40 300 6 30 200 4 20 2 10 100 0 0 0 29-Dec-20 28-Jan-21 27-Feb-21 29-Mar-21 Mar-20 May-20 Jul-20 Sep-20 Nov-20 Jan-21 Mar-21 Source: OWID, Standard Chartered Research Source: CEIC, Standard Chartered Research Standard Chartered Global Research | 31 March 2021 4 Global Focus – Economic Outlook Q2-2021 India has seen a new surge in In India, more expansionary fiscal policy should support recovery momentum cases, but targeted restrictions overview (see India – FY22: A tale of two halves). We expect a sharp recovery to double-digit Global should allow more activity than growth in FY22 (ending March 2022), driven by consumption and public capex. India’s earlier lockdowns economic recovery has been uneven to date, with the informal sector lagging the formal sector and rural demand growing faster than urban demand. Policy – especially monetary policy – will need to remain supportive to sustain the recovery. Higher oil Geopolitical prices pose a risk, as do obstacles to vaccinating India’s large population. Localised economics COVID outbreaks are a concern. Case numbers have recently surged to their highest since October 2020. We do not expect the majority of the population to be vaccinated until 2022, suggesting that economic activity remains vulnerable to restrictions during episodes of higher infections. The pace of recovery diverges in The pace of recovery also diverges across the rest of Asia. Developing domestic Asia Asia; strong exports and successful pandemic situations are a key driver of this divergence. Taiwan and Vietnam are pandemic management support among the few economies that started 2021 with GDP above pre-COVID levels. Strong growth in Taiwan and Vietnam external demand and successful domestic pandemic management support the positive growth outlook for these economies. In contrast, an early-year surge in infections in Indonesia and Malaysia has negatively affected their 2021 outlook (we downgraded MENAP our growth forecasts for these economies earlier this year). The situation has since stabilised, but not without affecting their growth recoveries. Similarly, we have downgraded our 2021 GDP growth forecast for Japan, partly due to the six-week emergency lockdown in January-February. In domestically driven economies In domestically driven economies such as Indonesia and the Philippines, the pace of Africa like Indonesia and the Philippines, vaccine rollout will be particularly important to the resumption of activity. In the the pace of vaccine rollout will be Philippines, household consumption accounts for c.72% of GDP and contracted 7.9% important in 2020. The economy is now seeing a resurgence of infections to the
Recommended publications
  • In the United States District Court for the District Of
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES, LLC and ) FOREST LABORATORIES ) HOLDINGS, LTD., ) ) Plaintiffs, ) ) v. ) Civ.No.14-1119-SLR ) SIGMAPHARM LABORATORIES, LLC, ) et al., ) ) Defendants. ) Jack B. Blumenfeld, Esquire and Maryellen Noreika, Esquire of Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware. Counsel for Plaintiffs. Of Counsel: Howard W. Levine, Esquire, Sanya Sukduang, Esquire, Jonathan R. Davies, Esquire, Courtney B. Gasp, Esquire, and Charles E. Lipsey, Esquire of Finnegan, Henderson, Farabow, Garrett & Dunner LLP. John C. Phillips, Esquire, David A. Bilson, Esquire and Megan C. Haney of Phillips, Goldman, Mclaughlin & Hall, P.A., Wilmington, Delaware. Counsel for Defendant Sigmapharm Laboratories, LLC. Of Counsel: Anthony G. Simon, Esquire, Anthony R. Friedman, Esquire, Benjamin R. Askew, Esquire, and Michael P. Kella, Esquire of The Simon Law Firm, P.C. Karen Elizabeth Keller, Esquire and Jeffrey Thomas Castellano, Esquire of Shaw Keller, LLP, Wilmington, Delaware. Counsel for Defendants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, and West-Ward Pharmaceutical Corp. Of Counsel: lmron T. Aly, Esquire, Joel M. Wallace, Esquire, and Helen H. Ji, Esquire of Schiff Hardin LLP. Richard D. Kirk, Esquire, Stephen B. Brauerman, Esquire and Sara E. Bussiere, Esquire of Bayard, P.A., Wilmington, Delaware. Counsel for Defendant Breckenridge Pharmaceutical, Inc. Of Counsel: Beth D. Jacob, Esquire, Clifford Katz, Esquire, and Malavika A. Rao, Esquire of Kelley, Drye & Warren LLP. Karen Pascale, Esquire and Pilar G. Kraman, Esquire of Young, Conaway, Stargatt & Taylor, LLP, Wilmington, Delaware. Counsel for Defendants Alembic Pharmaceuticals Ltd., Alembic Global Holding SA and Alembic Pharmaceuticals, Inc. Of Counsel: Steven J. Lee, Esquire, Michael K.
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
    29 January 2021 EMA/94907/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report COVID-19 Vaccine AstraZeneca Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ........................................................................................ 12 2.1.2. Epidemiology and risk factors ........................................................................... 12 2.1.3. Aetiology and pathogenesis .............................................................................
    [Show full text]
  • Astrazeneca-Oxford Vaccine Approved for Use in the U.K
    P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe.
    [Show full text]
  • United States District Court for the District of Columbia
    Case 1:12-cv-00472-BAH Document 42 Filed 07/05/12 Page 1 of 49 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ASTRAZENECA PHARMACEUTICALS LP, Plaintiff, v. Civil Action No. 12-00472 (BAH) Judge Beryl A. Howell FOOD AND DRUG ADMINISTRATION, et al., Defendants. AMENDED MEMORANDUM OPINION Plaintiff AstraZeneca Pharmaceuticals LP (“AstraZeneca”) has manufactured the drug quetiapine fumarate (“quetiapine”) under the brand name Seroquel® (“Seroquel”) since 1997 without generic competition. AstraZeneca brought this lawsuit, which presents a question of statutory interpretation, against the Food and Drug Administration, Margaret A. Hamburg, M.D., Commissioner of Food and Drugs, and Kathleen Sebelius, Secretary of Health and Human Services (collectively, “the FDA”), to challenge the FDA’s approval, on March 27, 2012, of generic versions of Seroquel. See Complaint, ECF No. 1 (“Compl.”), ¶ 3. AstraZeneca believes that, under the plain language of 21 U.S.C. § 355(j)(5)(F)(iv), codifying Section 505(j)(5)(F)(iv) of the Federal Food, Drug, and Cosmetic Act (“FDCA”), it is entitled to total market exclusivity until December 2, 2012 for the safety information encapsulated in “Table 2,” which was approved for all Seroquel labels on December 2, 2009 and must be included on the labels of all generic versions of quetiapine. Based upon this belief, AstraZeneca seeks a judgment that the FDA’s recent approval of generic versions of quetiapine, while AstraZeneca retains exclusivity over Table 2, violated AstraZeneca’s exclusivity rights and was arbitrary, capricious, and contrary to law. 1 Case 1:12-cv-00472-BAH Document 42 Filed 07/05/12 Page 2 of 49 Pending before the Court are Cross-Motions for Summary Judgment filed by AstraZeneca, ECF No.
    [Show full text]
  • Cephalon Provigil
    r* jfS* 1 ll JS 44 {Rev. 07/16) SHEET The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose ofinitiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.) 1. (a) PLAINTIFFS DEFENDANTS State of New York, et al. Cephalon, Inc. et al. (b) County of Residence of First Listed Plaintiff County of Residence of First Listed Defendant (EXCEPT IN U.S. PLAINTIFF CASES) (IN U.S. PLAINTIFF CASES ONLY) NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED. (c) Attorneys (Firm Name, Address, and Telephone Number) Attorneys (If Known) Office of the Attorney General, Commonwealth of Pennsylvania, 14® Floor Jay Lefkowitz, Kirkland & Ellis, 601 Lexington Avenue, New York, NY 10022 Strawberry Square, Harrisburg, PA 17120(717)787-4530 (212)446-4800 II. BASIS OF JURISDICTION (Placean "X" in One Box Only) III. CITIZENSHIP OF PRINCIPAL PARTIES (Placean "X" inOne Box for Plaintiff (For Diversify Cases Only) and One Box for Defendant) • 1 U.S. Government ^ 3 Federal Question PTF DEF PTF DEF Plaintiff (U.S. Government Not a Party) Citizen of This State Q 1 • 1 Incorporated or Principal Place Q 4 HI 4 of Business In This State l~l 2 U.S. Government • 4 Diversity Citizen of Another State • 2 Q 2 Incorporated and Principal Place G 5 Q 5 Defendant (Indicate Citizenship of Parties in Item III) of Business In Another State Citizen or Subject of a Q3 D 3 Foreign Nation D 6 06 Foreign Country IV.
    [Show full text]
  • Constituents & Weights
    2 FTSE Russell Publications 19 August 2021 FTSE 100 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Group 0.59 UNITED GlaxoSmithKline 3.7 UNITED RELX 1.88 UNITED KINGDOM KINGDOM KINGDOM Admiral Group 0.35 UNITED Glencore 1.97 UNITED Rentokil Initial 0.49 UNITED KINGDOM KINGDOM KINGDOM Anglo American 1.86 UNITED Halma 0.54 UNITED Rightmove 0.29 UNITED KINGDOM KINGDOM KINGDOM Antofagasta 0.26 UNITED Hargreaves Lansdown 0.32 UNITED Rio Tinto 3.41 UNITED KINGDOM KINGDOM KINGDOM Ashtead Group 1.26 UNITED Hikma Pharmaceuticals 0.22 UNITED Rolls-Royce Holdings 0.39 UNITED KINGDOM KINGDOM KINGDOM Associated British Foods 0.41 UNITED HSBC Hldgs 4.5 UNITED Royal Dutch Shell A 3.13 UNITED KINGDOM KINGDOM KINGDOM AstraZeneca 6.02 UNITED Imperial Brands 0.77 UNITED Royal Dutch Shell B 2.74 UNITED KINGDOM KINGDOM KINGDOM Auto Trader Group 0.32 UNITED Informa 0.4 UNITED Royal Mail 0.28 UNITED KINGDOM KINGDOM KINGDOM Avast 0.14 UNITED InterContinental Hotels Group 0.46 UNITED Sage Group 0.39 UNITED KINGDOM KINGDOM KINGDOM Aveva Group 0.23 UNITED Intermediate Capital Group 0.31 UNITED Sainsbury (J) 0.24 UNITED KINGDOM KINGDOM KINGDOM Aviva 0.84 UNITED International Consolidated Airlines 0.34 UNITED Schroders 0.21 UNITED KINGDOM Group KINGDOM KINGDOM B&M European Value Retail 0.27 UNITED Intertek Group 0.47 UNITED Scottish Mortgage Inv Tst 1 UNITED KINGDOM KINGDOM KINGDOM BAE Systems 0.89 UNITED ITV 0.25 UNITED Segro 0.69 UNITED KINGDOM
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Vanguard FTSE 100 Index Unit Trust GBP Inc Inception Date: 08 November 2016
    Vanguard® Factsheet | 31 August 2021 Vanguard FTSE 100 Index Unit Trust GBP Inc Inception date: 08 November 2016 Total assets (million) £650 | Share class assets (million) £82 as at 31 August 2021 Minimum Trading initial Investment Index frequency investment* ISIN SEDOL Bloomberg Citi MexID SRRI‡ IA Sector structure ticker Domicile Settlement (cut-off) 1,000,000 GB00BD3RZ251 BD3RZ25 VAFTIGI NGLZ VRXXD 6 — UCITS UKXNUK United T+2 Daily (12:00 Kingdom London Time) Management Charges Ongoing Charges Figure† 0.06% †The Ongoing Charges Figure (OCF) covers administration, audit, depository, legal, registration and regulatory expenses incurred in respect of the Funds. When you invest with any fund manager, you pay a number of charges, starting with the Annual Management Charge (AMC) which covers the fund manager's costs of managing the fund. The AMC plus ongoing running costs and other operational expenses make up the fund's total 'ongoing charges figure'. Objectives and investment policy • The fund is a passive fund. • The Fund seeks to track the performance of the FTSE 100 Index (the “Index”). • The Index is a market-capitalisation weighted index representing the performance of the 100 largest companies traded on the London Stock Exchange that pass screening for size and liquidity. Market-capitalisation is the value of a company’s outstanding shares in the market and shows the size of a company. • The Fund attempts to: 1. Track the performance of the Index by investing in all constituent shares of the Index in the same proportion as the Index. Where not practicable to fully replicate, the Fund will use a sampling process.
    [Show full text]
  • COVID-19 Vaccine Safety Update for Vaxzevria
    14 July 2021 COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB The safety of Vaxzevria is continuously monitored and safety updates are regularly provided to the public. This document outlines the outcomes from the assessment of emerging worldwide safety data carried out by EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) (see section 1). It also contains high-level information from the reporting of suspected adverse reactions, which PRAC takes into account in its assessments (see section 2). This safety update follows the update of 18 June 2021. Main outcomes from PRAC's latest safety assessment Vaccinated persons need to seek immediate medical attention if they develop weakness and paralysis in the extremities, possibly progressing to the chest and face, after vaccination with Vaxzevria, as these could be signs of Guillain-Barré syndrome. The product information will be updated. Vaxzevria is effective in preventing COVID-19. www.ema.europa.eu COVID-19 vaccine safety update VAXZEVRIA The safety updates are published regularly at COVID-19 vaccines: authorised. All published safety updates for Vaxzevria are available at Vaxzevria: safety updates. Since its marketing authorisation in the European Union (EU) on 29 January 2021 until 4 July 2021, more than 58.4 million doses of Vaxzevria have been administered in the EU/EEA1. More than 58.4 million doses administered in EEA 1. Updates on safety assessments for Vaxzevria Based on new safety data, including the latest Monthly Summary Safety Report (MSSR)2 from the marketing authorisation holder and data reported by patients and healthcare professionals to EudraVigilance (see section 2), PRAC assessed the following at its meeting held 5 to 8 July 2021: Guillain-Barré syndrome (GBS) PRAC assessed cases of Guillain-Barré syndrome (GBS) reported after vaccination with Vaxzevria.
    [Show full text]
  • Declarations of Interest Thorax: First Published As 10.1136/Thoraxjnl-2016-209333.467 on 15 November 2016
    Declarations of interest Thorax: first published as 10.1136/thoraxjnl-2016-209333.467 on 15 November 2016. Downloaded from P55 BENEFITS OF TIOTROPIUM/OLODATEROL ON B Make has received honoraria for participation in NOVELTY SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN planning meeting, and has received grant funding, participated in PATIENTS WITH MODERATE TO SEVERE COPD WITH advisory boards and provided non-branded talk for AstraZeneca. CHRONIC BRONCHITIS AND/OR EMPHYSEMA He has received honoraria for participation in medical advisory boards for Aerocrine, Boehringer-Ingelheim, CSL Bering, GlaxoS- 10.1136/thoraxjnl-2016-209333.467 mithKline, Forest, Novartis, Spiration, Theravance, and Suno- vion. He has participated in research studies funded by Boehringer-Ingelheim, GlaxoSmithKline, Pfizer, Forest, Sunovian. GT Ferguson, during the conduct of the study, reports grants, RJ Martin has received consulting fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingel- Teva, Genentech, Boeringer Ingelheim, and PMD. His institution heim and, outside the submitted work, grants, personal fees and has received grants from NHLBI (AsthmaNet) and MedImmune. non-financial support from Boehringer Ingelheim, personal fees He has also received travel/accommodation/meeting expenses from GlaxoSmithKline, grants and personal fees from Novartis, from the Respiratory Effectiveness Group. AstraZeneca, Pearl Therapeutics and Sunovion, and grants from I Pavord has received speaker’s honoraria for speaking at Forest. sponsored meetings from Astra Zeneca, Boehringer Ingelheim, R Abrahams reports grants and personal fees from Boehringer Aerocrine, Almirall, Novartis, and GSK and a payment for organ- Ingelheim during the conduct of the study and, outside of this ising an educational event from AZ.
    [Show full text]
  • PHILADELPHIA's TALENT POOL Corporate Membership
    ® Corporate Membership BUILD YOUR TALENT PIPELINE IN PHILADELPHIA 1. Recruiting the best talent is tougher than ever in this job market. Each year, Campus Philly engages more than 60,000 college students at 60+ regional and national colleges and universities, including nine HBCUs. Align your company with our mission, increase your employer brand visibility and get a head start on recruiting before they even graduate. 2. Diversifying your talent pipeline is a challenge. Campus Philly can help you meet a wider audience. 45% of students on regional Philadelphia campuses are students of color and 60% are female. More than one-third of students at Campus Philly career events are first generation college students. 3. Retaining Millennials and GenZ is difficult. On average, college students expect to have 2.8 jobs between graduation and their 10-year reunion and they identify opportunity for growth as the top factor in choosing an employer. Campus Philly can help you onboard, engage and Top 3 Reasons to Join to 3 Reasons Top develop these young professionals you’ve worked hard to recruit through our fun and unique place-based programming. Photo: Olivia Brosky Photo: UNDERGRADUATES INCREASE engaged by Campus Philly annually in 25-34 year olds with degrees since 2000 IN NEW EARNINGS annually in Greater Philadelphia PHILADELPHIA’S TALENT POOL 2020 Corporate Membership: Levels and Benefits Corporate members support and participate in Campus Philly’s mission and programs all year round. They are recognized as our supporters and have exclusive access
    [Show full text]